Inactive Instrument

Viracta Therapeutics, Inc. Nasdaq

US92765F1084

Biotechnology & Medical Research

Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from Russell Microcap Value Index

June 26, 2020 at 12:00 am

Latest news about Viracta Therapeutics, Inc.

Viracta Therapeutics Appoints Michael Faerm CFO	05-14	MT
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	05-14	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	04-15	CI
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	04-01	CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	03-21	MT
Viracta Therapeutics, Inc. Announces Executive Changes	03-20	CI
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	03-20	CI
North American Morning Briefing : Inflation -2-	03-15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Viracta Therapeutics, Inc. Provides Clinical Update	01-04	CI
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	12-04	CI
RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	11-10	MT
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31	MT
Transcript : Viracta Therapeutics, Inc. - Special Call	23-10-04
Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer	23-08-08	CI
HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating	23-07-05	MT
Viracta Therapeutics to Expand Cohort of Patients in Virus-Associated Cancers Clinical Trial	23-06-28	MT
Viracta Therapeuticsâ€™ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma	23-06-28	CI
RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating	23-05-09	MT

Chart Viracta Therapeutics, Inc.

Duration

Period

More charts

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research

Viracta Therapeutics, Inc. Nasdaq

Equities

US92765F1084

Biotechnology & Medical Research

Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from Russell Microcap Value Index

Latest news about Viracta Therapeutics, Inc.

Chart Viracta Therapeutics, Inc.

Company Profile

Sector Other Biotechnology & Medical Research